ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 17 of 447 for:    Osteosarcoma

an Istitution Experience on Parosteal OsTeosarcoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03768076
Recruitment Status : Recruiting
First Posted : December 7, 2018
Last Update Posted : December 14, 2018
Sponsor:
Information provided by (Responsible Party):
Istituto Ortopedico Rizzoli

Brief Summary:
single institution cases series review of histological and clinical data

Condition or disease
Parosteal Osteosarcoma

Detailed Description:
Investigators will review all the cases with a diagnosis of primary parosteal osteosarcoma treated at the Rizzoli Institute from 1900 up to 31 July 2018, retrospectively.

Study Type : Observational
Estimated Enrollment : 220 participants
Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Parosteal OsTeosarcoma: a Single Istitution Experience
Actual Study Start Date : November 30, 2018
Estimated Primary Completion Date : November 1, 2019
Estimated Study Completion Date : November 30, 2019

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. retrospective analysis of cases of Parosteal osteosarcoma [ Time Frame: at baseline (Day0) ]
    Investigators will exam the presence of progression (dedifferentiation) areas and the relationship of these factors to individual outcome.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Sampling Method:   Non-Probability Sample
Study Population
male and female with diagnosis of parosteal osteosarcoma treated at Rizzoli institute from 01 Jan 1900 to 31 Jul 2018
Criteria

Inclusion Criteria:

  • Male and female patients treated at Rizzoli Institute from 01 Jan 1900 to 31 Jul 2018
  • Diagnosis of parosteal osteosarcoma
  • Written informed consent prior to any study-specific analysis and/or data collection

Exclusion Criteria:

• Patients with histological diagnosis different from parosteal osteosarcoma


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03768076


Contacts
Contact: Alberto Righi +390516366 ext 655 alberto.righi@ior.it

Locations
Italy
Istituto ortopedico Rizzoli Recruiting
Bologna, Italy, 40136
Contact: Alberto Righi, MD    051.63.66 ext 665    alberto.righi@ior.it   
Sponsors and Collaborators
Istituto Ortopedico Rizzoli
  Study Documents (Full-Text)

Documents provided by Istituto Ortopedico Rizzoli:
Study Protocol  [PDF] September 1, 2018


Publications of Results:
Responsible Party: Istituto Ortopedico Rizzoli
ClinicalTrials.gov Identifier: NCT03768076     History of Changes
Other Study ID Numbers: POsT
First Posted: December 7, 2018    Key Record Dates
Last Update Posted: December 14, 2018
Last Verified: November 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: No Individual Patient Data sharing plan has been implemented

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Osteosarcoma
Osteosarcoma, Juxtacortical
Neoplasms, Bone Tissue
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms
Sarcoma